Fluvastatin

Better Known as: Lescol

• Marketed By: Novartis
  
• Major Indication: Hyperlipidemia & High Cholesterol (Hypercholesterolemia)
  
• Drug Class: HMGR Inhibitor or Statin
• Date of FDA Approval (Patent Expiration): 1993 (2011)
  
• 2000 Sales: $430 Million
• Importance: Was largely replaced by Lipitor. Statins are so ubiquitous, doctors have even suggested handing them out with fast food. See: the article
  
• See Pharmaceutical Drugs for more information about other drugs and disorders

Mechanism of Action

Fluvastatin is an inhibitor of HMG-CoA Reductase (HMGR), a highly responsible for the committed step in cholesterol synthesis.^[1] Fluvastatin, like most of the statins, via a number of polar interactions with the "cis loop" of HMGR, particularly residues Ser 684, Asp 690, Lys 691, Lys 692, and hydrogen bond interactions between Glu 559 and Asp 767 with the O5-hydroxyl of the statins. Van der Waals interactions between Leu 562, Val 683, Leu 853, Ala 856, and Leu 857 of HMGR and hydrophobic ring structures of Fluvastatin contribute to binding as well.^[2] These interactions help Fluvastatin outcompete HMG-CoA, the substrate of HMGR, in binding to HMGR.^[3]

For References, See References